CClinicalTrials.gg
CompletedNCT03273699Updated Apr 10, 2019

Mindfulness Meditation Utilizing an EEG Biofeedback Device for the Treatment for Obsessive Compulsive Disorder

An interventional study of Mindfulness in Obsessive-Compulsive Disorder, sponsored by Sunnybrook Health Sciences Centre. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-10.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The Frederick W. Thompson Anxiety Disorders Centre has experienced significant demand for services related to the treatment of Obsessive Compulsive Disorder (OCD), resulting in a significant wait time for service. Although Cognitive Behavior Therapy (CBT) is the most efficacious treatment intervention for OCD, there is a growing literature indicating the mindfulness based approaches can be beneficial in terms of managing acute mood and anxiety symptoms as well as reducing relapse risk following treatment.The goal of this study is to examine the potential benefits of using a consumer grade EEG-based biofeedback device that allows clients to engage in home based mindfulness meditation practices while they are waiting to receive clinical services. Specifically, this study will investigate the effects of meditation home practice on symptom alleviation, as related to specific OCD related cognitive processes.

Read the detailed description

The goal of this study is to examine the potential benefits of using a consumer grade EEG-based biofeedback device that allows clients to engage in home based mindfulness meditation practices while they are waiting to receive clinical services. Specifically, this study will investigate the effects of meditation home practice on symptom alleviation, as related to specific OCD related cognitive processes.The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the "GraphPad Quick Calcs" online calculator which offers simple random allocation into equal-sized groups.Outcome measures will involve ratings of OCD symptom severity, OCD beliefs, mindfulness, and use of thought control strategies. At baseline, mid treatment (session 4), and post intervention, participants will complete the Yale-Brown Obsessive Compulsive Scale, Obsessive Compulsive Inventory, Obsessive Beliefs Questionnaire, Five Factor Mindfulness Questionnaire, Thought Control Questionnaire, Acceptance and Action Questionnaire, Mind Wandering Scale and the Metacognitions Questionnaire. Once per week, participants will complete the YBOCS, TCQ, and MW. This weekly data will be collected online using the "Survey Monkey" web portal. Daily practice data from the EEG headsets will be automatically uploaded to an encrypted server.

02

Conditions studied

  • Obsessive-Compulsive Disorder
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • All inclusion and exclusion criteria are consistent with the established guidelines for our service - there are no additional study specific criteria. Potential subjects are referred to the service with a query of OCD. Due to the nature of the assessment procedures, which include English-language self-report questionnaires and scales, the ability to communicate in written and spoken English is an inclusion criterion. disorder

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria include a) those with active substance abuse/dependence, b) suspected organic pathology, c) recent suicide attempt/active suicidality, d) active bipolar, psychotic disorder or post-traumatic stress
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Mindfulness

    The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the "GraphPad Quick Calcs" online calculator which offers simple random allocation into equal-sized groups

    Device: Mindfulness

  • No intervention
    Control

    The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the "GraphPad Quick Calcs" online calculator which offers simple random allocation into equal-sized groups

Interventions

  • DeviceMindfulness

    Clients will use a consumer grade EEG device that provides guided mindfulness home practices

05

What researchers measure

Primary outcomes

  1. Yale-Brown Obsessive Compulsive Scale (YBOCS)

    A self-report inventory of obsessive compulsive symptoms

    Time frame: Completed once per week, for eight weeks

Secondary outcomes

  1. Obsessive Compulsive Inventory

    Self-report measure of obsessive compulsive symptoms

    Time frame: Completed at three timepoints - week 1, week 4, week 8

  2. Obsessive Beliefs Questionnaire

    Self-report measure of OCD beliefs

    Time frame: Completed at three timepoints - week 1, week 4, week 8

  3. Five Factor Mindfulness Questionnaire

    Self-report measure of mindfulness

    Time frame: Completed at three timepoints - week 1, week 4, week 8

  4. Thought Control Questionnaire

    Self-report measure of use of thought control strategies

    Time frame: Completed at three timepoints - week 1, week 4, week 8

  5. Acceptance and Action Questionnaire

    Self-report measure of experiential avoidance

    Time frame: Completed at three timepoints - week 1, week 4, week 8

  6. Mind Wandering Scale

    Self-report measure of mind wandering

    Time frame: Completed at three timepoints - week 1, week 4, week 8

  7. Metacognitions Questionnaire

    Self-report measure of metacognitive strategies

    Time frame: Completed at three timepoints - week 1, week 4, week 8

06

Study locations

1 site
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N3M5, Canada
07

References and documents

Publications

  • Bhayee S, Tomaszewski P, Lee DH, Moffat G, Pino L, Moreno S, Farb NA. Attentional and affective consequences of technology supported mindfulness training: a randomised, active control, efficacy trial. BMC Psychol. 2016 Nov 29;4(1):60. doi: 10.1186/s40359-016-0168-6. PubMed 27894358 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 1, 2017
  • Informed consent form · Sep 1, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03273699
Lead sponsor
Sunnybrook Health Sciences Centre
Responsible party
Sponsor
First posted
Sep 6, 2017
Start date
Apr 10, 2017
Primary completion
Jan 31, 2019
Completion
Jan 31, 2019
Last update
Apr 10, 2019

Study contacts

Peggy Richter, M.D.
study director · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion